



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

7/2
42903
RECEIVED
APR 17 2003
TECH CENTER 1600/2900

Application of:

Ralph LIPP et al.

Group Art Unit 1615

Serial No.: 10/022,834

Examiner: Young

Filed: December 20, 2001

For: TRANSDERMAL SYSTEM THAT CONTAINS A NEW HIGHLY POTENT
GESTAGEN

AMENDMENT AND RESPONSE

Assistant Commissioner for Patents
Washington, D. C. 20231

Sir:

In response to the office action dated 9 October 2002, please amend the above-identified application as follows:

IN THE CLAIMS:

Please amend claims 1-10 as follows:

1. (Currently Amended) A matrix ~~Matrix-transdermal system that contains~~ comprising (21S)-21-hydroxy-21-methyl-14,1-7-ethano-19-norpregna-4,9,15-triene-3,20-dione, ~~characterized in that the~~ and a matrix comprises comprising polyacrylate adhesive.

2. (Currently Amended) A transdermal ~~Transdermal~~ system according to claim 1, wherein the polyacrylate adhesive is a copolymer of at least two of the following monomers: 2-ethylhexylhexylacrylate, hydroxyethylhexylacrylate, vinyl acetate, or vinyl pyrrolidone.

3. (Currently Amended) A transdermal ~~Transdermal~~ system according to claim 2, wherein the polyacrylate adhesive is a copolymer that consists of 2-ethylhexylacrylate and hydroxyethylacrylate (Gelva-sup-(R)) or a copolymer of these monomers with vinyl acetate